当前位置: 首页 > 期刊 > 《中国现代医生》 > 2010年第13期
编号:11898133
硼替佐米联合地塞米松治疗多发性骨髓瘤的临床研究(3)
http://www.100md.com 2010年5月5日 《中国现代医生》 2010年第13期
     [5] Mitsiades N,Mitsiades CS,Richardson PG,et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents:therapeutic applications[J]. Blood,2003,101:2377-2380.

    [6] Jagannath S,Durie BG,Wolf J,et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J]. Br J Haematol,2005,129:776-783.

    [7] 张之南,沈梯. 血液病诊断及疗效标准[M]. 北京:科学出版社,2001:218.

    [8] Blade J,Samson D,Reece D,et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem celltransplantation. Myeloma Subco- mmitte for the EBMT[J]. Br J haematol,1998,102:1115-1123.

    [9] Jagannath S,Barlogie B,Berenson J,et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J]. Br J Haematol,2004, 127(2):165-172.

    [10] Richardson PG,Sonneveld P,Schuster MW,et al. Bortezomib or high- dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med JT-The New England Journal of Medicine,2005,352(24):2487-2498.

    (收稿日期:2010-01-28), 百拇医药(宋春鸽 画宝勇)
上一页1 2 3